Yiwei Wang1,2, Gerson Hernandez1,2, Wendy J Mack3, Lon S Schneider3, Fei Yin1,2, Roberta D Brinton1,2. 1. School of Pharmacy, University of Southern California, Los Angeles, CA. 2. Center for Innovation in Brain Science and Department of Pharmacology, University of Arizona, Tucson, AZ. 3. Keck School of Medicine, University of Southern California, Los Angeles, CA.
Abstract
OBJECTIVE:PhytoSERM is a selective estrogen receptor beta (ERβ) modulator comprised of three phytoestrogens: genistein, daidzein, and S-equol. The PhytoSERM formulation promotes estrogenic action in the brain while largely inactive or inhibitory in reproductive tissue. A phase Ib/IIa clinical trial (ClinicalTrial.gov ID: NCT01723917) of PhytoSERM demonstrated safety and pharmacokinetics profile of PhytoSERM. While this study was not powered for efficacy analysis, we conducted a pilot, retrospective analysis to identify potential responders to PhytoSERM treatment, and to determine the optimal populations to pursue in a phase II clinical trial of efficacy of the PhytoSERM formulation. METHODS: In this retrospective analysis involving 46 participants (n = 16, placebo; n = 18, 50 mg/d PhytoSERM; and n = 12, 100 mg/d PhytoSERM), the therapeutic effect of PhytoSERM was stratified by 2 genetic risk modulators for Alzheimer's disease: mitochondrial haplogroup and APOE genotype. RESULTS: Our retrospective responder analysis indicated that participants on 50 mg of daily PhytoSERM (PS50) for 12 weeks significantly reduced hot flash frequency compared with their baseline (mean [95% CI])-1.61, [-2.79, -0.42], P = 0.007). Participants on 50 mg of PhytoSERM also had significantly greater reduction in hot flash frequency at 12 weeks compared with the placebo group (-1.38, -0.17 [median PS50, median placebo], P = 0.04). Fifty milligrams of daily PhytoSERM also preserved cognitive function in certain aspects of verbal learning and executive function. Our analysis further suggests that mitochondrial haplogroup and APOE genotype can modify PhytoSERM response. CONCLUSION: Our data support a precision medicine approach for further development of PhytoSERM as a safe and effective alternative to hormone therapy for menopause-associated hot flash and cognitive decline. While definitive determination of PhytoSERM efficacy is limited by the small sample size, these data provide a reasonable rationale to extend analyses to a larger study set powered to address statistical significance.
RCT Entities:
OBJECTIVE:PhytoSERM is a selective estrogen receptor beta (ERβ) modulator comprised of three phytoestrogens: genistein, daidzein, and S-equol. The PhytoSERM formulation promotes estrogenic action in the brain while largely inactive or inhibitory in reproductive tissue. A phase Ib/IIa clinical trial (ClinicalTrial.gov ID: NCT01723917) of PhytoSERM demonstrated safety and pharmacokinetics profile of PhytoSERM. While this study was not powered for efficacy analysis, we conducted a pilot, retrospective analysis to identify potential responders to PhytoSERM treatment, and to determine the optimal populations to pursue in a phase II clinical trial of efficacy of the PhytoSERM formulation. METHODS: In this retrospective analysis involving 46 participants (n = 16, placebo; n = 18, 50 mg/d PhytoSERM; and n = 12, 100 mg/d PhytoSERM), the therapeutic effect of PhytoSERM was stratified by 2 genetic risk modulators for Alzheimer's disease: mitochondrial haplogroup and APOE genotype. RESULTS: Our retrospective responder analysis indicated that participants on 50 mg of daily PhytoSERM (PS50) for 12 weeks significantly reduced hot flash frequency compared with their baseline (mean [95% CI])-1.61, [-2.79, -0.42], P = 0.007). Participants on 50 mg of PhytoSERM also had significantly greater reduction in hot flash frequency at 12 weeks compared with the placebo group (-1.38, -0.17 [median PS50, median placebo], P = 0.04). Fifty milligrams of daily PhytoSERM also preserved cognitive function in certain aspects of verbal learning and executive function. Our analysis further suggests that mitochondrial haplogroup and APOE genotype can modify PhytoSERM response. CONCLUSION: Our data support a precision medicine approach for further development of PhytoSERM as a safe and effective alternative to hormone therapy for menopause-associated hot flash and cognitive decline. While definitive determination of PhytoSERM efficacy is limited by the small sample size, these data provide a reasonable rationale to extend analyses to a larger study set powered to address statistical significance.
Authors: Rowan T Chlebowski; Garnet L Anderson; Margery Gass; Dorothy S Lane; Aaron K Aragaki; Lewis H Kuller; JoAnn E Manson; Marcia L Stefanick; Judith Ockene; Gloria E Sarto; Karen C Johnson; Jean Wactawski-Wende; Peter M Ravdin; Robert Schenken; Susan L Hendrix; Aleksandar Rajkovic; Thomas E Rohan; Shagufta Yasmeen; Ross L Prentice Journal: JAMA Date: 2010-10-20 Impact factor: 56.272
Authors: Joelle M van der Walt; Yulia A Dementieva; Eden R Martin; William K Scott; Kristin K Nicodemus; Charles C Kroner; Kathleen A Welsh-Bohmer; Ann M Saunders; Allen D Roses; Gary W Small; Donald E Schmechel; P Murali Doraiswamy; John R Gilbert; Jonathan L Haines; Jeffery M Vance; Margaret A Pericak-Vance Journal: Neurosci Lett Date: 2004-07-15 Impact factor: 3.046
Authors: Steven Jett; Eva Schelbaum; Grace Jang; Camila Boneu Yepez; Jonathan P Dyke; Silky Pahlajani; Roberta Diaz Brinton; Lisa Mosconi Journal: Front Aging Neurosci Date: 2022-07-19 Impact factor: 5.702
Authors: Jaclyn M Eissman; Logan Dumitrescu; Emily R Mahoney; Alexandra N Smith; Shubhabrata Mukherjee; Michael L Lee; Phoebe Scollard; Seo Eun Choi; William S Bush; Corinne D Engelman; Qiongshi Lu; David W Fardo; Emily H Trittschuh; Jesse Mez; Catherine C Kaczorowski; Hector Hernandez Saucedo; Keith F Widaman; Rachel F Buckley; Michael J Properzi; Elizabeth C Mormino; Hyun Sik Yang; Theresa M Harrison; Trey Hedden; Kwangsik Nho; Shea J Andrews; Douglas Tommet; Niran Hadad; R Elizabeth Sanders; Douglas M Ruderfer; Katherine A Gifford; Xiaoyuan Zhong; Neha S Raghavan; Badri N Vardarajan; Margaret A Pericak-Vance; Lindsay A Farrer; Li San Wang; Carlos Cruchaga; Gerard D Schellenberg; Nancy J Cox; Jonathan L Haines; C Dirk Keene; Andrew J Saykin; Eric B Larson; Reisa A Sperling; Richard Mayeux; Michael L Cuccaro; David A Bennett; Julie A Schneider; Paul K Crane; Angela L Jefferson; Timothy J Hohman Journal: Brain Date: 2022-07-29 Impact factor: 15.255